An investigational pancreatic cancer drug that has not been approved by any regulator has now been distributed to physicians for more than 2,000 patients across nearly all 50 states and Puerto Rico, according to the company's second-quarter update. The disclosure is the first public measure of how widely daraxonrasib has been administered through the expanded access program since it opened in the spring.
Separately, the Food and Drug Administration has accepted the manufacturer's new drug application for review, moving the treatment from a compassionate use pathway toward a formal approval decision. Mark Goldsmith, chief executive of Revolution Medicines, described the period as one in which the company "rapidly translated unprecedented Phase 3 results for daraxonrasib into an active Expanded Access Program and the filing of our first New Drug Application."
For families facing metastatic pancreatic cancer, the practical meaning of these two developments is narrow but real. The drug is reaching community oncology practices, not only major academic centers, which changes the calculation for patients who cannot travel far for care.
The Numbers Behind the Expanded Access Program
The clinical result driving demand came from RASolute 302, a global phase 3 trial of 500 patients with metastatic pancreatic ductal adenocarcinoma who had already received one line of treatment. Median overall survival was 13.2 months with the oral drug compared with 6.7 months with standard chemotherapy, with a hazard ratio of 0.40. Among patients with RAS G12 mutations, who made up 91.8 percent of the trial, progression-free survival was 7.3 months versus 3.5 months, and the confirmed objective response rate was 33.2 percent versus 11.8 percent.
Those are the strongest randomized results reported in this disease, and they were presented at the American Society of Clinical Oncology annual meeting with simultaneous publication in the New England Journal of Medicine. Brian Wolpin of Dana-Farber Cancer Institute, who presented the findings, said the trial met all primary and key secondary endpoints with statistically significant and clinically meaningful improvements in survival, response, and quality of life, according to coverage of the plenary presentation.
Two limits belong alongside those numbers. The study was sponsored by the manufacturer, which developed and funded the drug, and Wolpin is among its investigators. And a median survival of just over a year is a meaningful gain rather than a cure, in a disease where the large majority of people diagnosed with metastatic disease do not survive five years. Adverse events of grade 3 or higher occurred in 61.8 percent of patients taking the drug, compared with 69.6 percent on chemotherapy. Rash and mouth inflammation were the side effects that most often forced a dose reduction.
Cost, Insurance, and the Bills That Still Arrive
Expanded access, sometimes called compassionate use, allows patients who cannot enroll in a trial to receive an investigational drug outside of a trial. The FDA authorized this program two days after receiving the request, and requests must be submitted to the sponsor by a licensed U.S. physician on behalf of an eligible patient. A patient cannot apply directly.
The financial picture is frequently misunderstood. Sponsors commonly provide investigational drugs at no charge under expanded access, but that does not make participation free. Insurers generally do not pay for investigational products, and the associated care, including office visits, imaging, laboratory monitoring, and management of side effects, is billed as usual. Families should ask the cancer center's financial navigator what will and will not be billed before starting.
Access also depends on institutional participation. Each center must open the protocol, which happens site by site rather than all at once, and smaller practices may take longer because opening a protocol requires administrative and pharmacy capacity that community sites do not always have on hand. A patient at a practice that has not opened it can ask for a referral to one that has, though travel and time away from work carry their own cost.
Molecular Testing Remains the Gate for Every Route
Neither trial enrollment nor expanded access is possible without documented RAS mutation status, which makes molecular tumor testing the practical starting point. The concrete step for a patient or caregiver is to ask the treating oncologist two questions: whether the tumor has been tested for RAS mutations, and whether the center has opened either a trial or the expanded access protocol.
MedicalDaily previously reported on who qualifies for the expanded access route, and the eligibility structure has not changed. What has changed is scale, and the fact that the drug is now moving through community practices as well as academic centers.
Patients should be cautious about anyone offering this drug outside a physician-submitted request through the sponsor. There is no legitimate consumer route to an investigational medicine, and no one should stop or alter an existing cancer treatment in anticipation of obtaining one.
Decisions Awaited from Regulators on Two Continents
The application under review by the FDA was selected for the agency's Commissioner's National Priority Voucher pilot program, which is intended to expedite the review of medicines addressing national health priorities. The drug also holds Breakthrough Therapy and Orphan Drug designations for previously treated metastatic pancreatic cancer with G12 mutations, according to reporting on the agency's handling of the application. No approval decision date has been made public.
In Europe, the European Medicines Agency has begun a phased review under a program designed to assess sections of the data as they become available, ahead of a full marketing authorization application. Swiss regulators granted orphan drug status.
Trials in earlier disease settings are ongoing, including studies in first-line metastatic disease and in patients receiving treatment after surgery. Those results will not be available for some time, and nothing currently supports use outside the previously treated metastatic setting.
The most important uncertainty is what approval would mean for cost and coverage. Once a drug moves from expanded access to the commercial market, the sponsor sets a price, insurers decide on placement, and patients who received it for free may face copays or prior authorization requirements. Neither the price nor the coverage terms are known. Families relying on the program now should ask their oncology team to plan for that transition rather than assume continuity.
Key Questions Answered
Is this drug approved? No. It remains investigational. The FDA has accepted a new drug application for review, and no approval decision has been announced.
How many patients have received it? The manufacturer reported that it has been distributed to physicians on behalf of more than 2,000 patients through expanded access across nearly all 50 states and Puerto Rico.
Who is eligible? Patients with previously treated metastatic pancreatic ductal adenocarcinoma who cannot enroll in an ongoing trial. Requests must come from a licensed U.S. physician to the sponsor.
What did the trial actually show? Median overall survival of 13.2 months versus 6.7 months with standard chemotherapy in 500 patients. It is a meaningful survival gain, not a cure.
Does insurance pay for it? Sponsors commonly supply investigational drugs at no charge, but associated visits, scans, laboratory work, and side-effect management are billed normally. Ask a financial navigator before starting.
What should a patient ask an oncologist first? Whether the tumor has been tested for RAS mutations, and whether the treatment center has opened a trial or the expanded access protocol.
What are the main side effects? Adverse events of grade 3 or higher occurred in about 62 percent of patients taking the drug in the trial, and rash and mouth inflammation were the most common causes of dose reductions.
